Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Neutralizing IL-23 and Its Targets May Improve Ankylosing Spondylitis

Lara C. Pullen, PhD  |  August 30, 2012

Researchers have identified a unique population of entheseal resident cells that can be activated by interleukin 23 (IL-23).1 When activated, the T cells produce IL-22 and activate signal transducer and activator of transcription 3 (STAT3)–dependent osteoblast-mediated bone remodeling. This finding may be key to understanding how dysregulation of IL-23 results in precise inflammation of the entheses. Up until now, the entheses has not been considered to be a site of resident immune surveillance.

Inflammation in the enthesis causes the painful symptoms of spondylarthritic disease. Spondylarthropies such as ankylosing spondylitis (AS) have also consistently been accompanied by an association with the human leukocyte antigen B27 (HLA-B27) and elevated levels of serum IL-23. Beyond this, the pathogenesis of AS and other spondylarthropies has been poorly understood, to the extent that there is a great deal of debate as to whether AS is a true antigen-specific autoimmune disease or an autoinflammatory condition.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Investigators have long been puzzled by the exact cause of the immune response in patients with AS. Recent findings have pointed to IL-23 as a key factor in spondylarthropathy, and therefore investigators used an experimental mouse model of systemic IL-23 overexpression to explore the issue further. Results from the current study have led the investigators to suggest that, in fact, dysregulated IL-23 biology is the fundamental to spondylarthropathy.

The IL-23 receptor (IL23-R) has previously been shown to control the expansion and elaboration of IL-17 during infection in wild-type mice. Sherlock and colleagues identified a population of CD3+CD4–CD8-IL–23R+, RAR-related orphan receptor γt (ROR-γt)+ T cells in the enthesis of mice. These cells appear to be primed to rapidly react to IL-23, resulting in the inflammation that is characteristic of spondylarthropathy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Daniel J. Cua, PhD, of Merck Research Laboratories in Pal Alto, Calif., the corresponding investigator of the study, explained via email, “It was very surprising to us that the enthesis … harbor a population of specific, highly potent immune cells. Until now, the dogma was that entheses are ‘acellular’ fibrous tissues. Indeed, we were only able to detect these unique cells using new technologies such as the IL-23R-eGFP reporter mice and high-resolution multiphoton microscopy. These immune cells are CD3+ T cells, but they do not have CD4 or CD8 and therefore don’t recognize antigen efficiently. Instead, they may be directly activated by stress signals and function like ‘innate immune cells’ that can directly respond to stress and injury.”

Page: 1 2 | Single Page
Share: 

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Ankylosing SpondylitisenthesisInterleukinResearchT-cells

Related Articles

    EULAR 2012: Does Arthritis Start in the Gut?

    August 8, 2012

    New research on the ties between bacteria and inflammatory disease.

    Doest Rheumatoid Arthritis Take a Toll?

    November 15, 2013

    Exploring the Toll background

    Connective Tissue Disorders Lack Societal Concern, Financial Support

    September 15, 2015

    “Love is the bone and sinew of my curse.” —Sylvia Plath Cutting the Cord Here’s the problem: No one grows up wanting to seek the cure for bursitis—or tendonitis or just about any of the other seemingly mundane maladies afflicting our body’s scaffolding. Meniscal tears, fasciitis, tendinopathies—the list is endless. Chances are, your college essay…

    Reading Rheum

    April 1, 2007

    Handpicked Reviews of Contemporary Literature

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences